According to The Fly, a Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. Analyst Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Valeant Pharm International (VRX)
Chen noted:
“. Post a beat and raise quarter, we reiterating our OW rating and 12-month price target of C$32 for BHC shares. We think a greater appreciation for BHC’s solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 15.9% and a 41.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Read also: Here’s Why AcelRx Pharmaceuticals (ACRX) Stock Skyrocketed Today
The the analyst consensus on Valeant Pharm International is currently a Moderate Buy rating.
Valeant Pharm International’s market cap is currently C$11.69B and has a P/E ratio of –. The company has a Price to Book ratio of 2.56.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
